Novartis' Gilenia Extension Trial Data Support Efficacy Of Low-Dose Version
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
New data on Novartis' investigational oral multiple sclerosis therapy Gilenia (fingolimod) strengthened the efficacy profile of the low dose 0.5 mg version of the drug and highlighted potential benefits of switching from Biogen Idec's Avonex (interferon beta-1a)
You may also be interested in...
Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June
Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.
Acorda's Novel Primary Endpoint For Ampyra Was Made Possible By A Supporting Scaffolding Of Secondary Analyses
Secondary analyses in the pivotal trials of Acorda’s Ampyra (dalfampridine) were of front-line interest to FDA as the agency grappled with the first indication for improving walking ability in multiple sclerosis patients and an untested primary endpoint.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011